Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve 1. To consider and approve the standalone Audited Financial Results for the quarter and year ended 31st March, 2025. 2. Any Other Business.

pdf

Choksi Laboratories Ltd.

25 Apr 2025

112.70

4.40%

Corp. Note

Choksi Laboratories Ltd - 526546 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyChoksi Laboratories Ltd 2CIN NO.L85195MP1993PLC007471 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 28.13 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Prakhar Dubey Designation: Company Secretary and Compliance Officer EmailId: compliance_officer@choksilab.com Name of the Chief Financial Officer: Vyangesh Choksi Designation: Chief Financial Officer EmailId: v.choksi@choksilab.com Date: 25/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Choksi Laboratories Ltd.

07 Apr 2025

112.70

4.40%

Company Update

Choksi Laboratories Ltd - 526546 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI (DP) Regulation, 2018 attached herewith the certificate issued by RTA of the company

pdf

Choksi Laboratories Ltd.

26 Mar 2025

112.70

4.40%

SAST

Choksi Laboratories Ltd - 526546 - Closure of Trading Window

BSE India

Intimation for closure of trading window w.e.f. 01.04.2025

pdf

Choksi Laboratories Ltd.

15 Feb 2025

112.70

4.40%

Company Update

CHOKSI LABORATORIES LTD. - 526546 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Extract of Unaudited Financial Results for the quarter and nine months ended 31st December, 2024 which has been published in the newspaper

pdf

Choksi Laboratories Ltd.

14 Feb 2025

112.70

4.40%

Corp. Note

CHOKSI LABORATORIES LTD. - 526546 - Integrated Filing (Financial)

BSE India

Integrated Financials for the quarter and nine month ended 31st December, 2024

pdf

Choksi Laboratories Ltd.

14 Feb 2025

112.70

4.40%

Result

CHOKSI LABORATORIES LTD. - 526546 - Financial Result For The Period Ended 31St December, 2025

BSE India

Considered and approved unaudited financial results for the quarter and nine month ended 31st December, 2025

pdf

Choksi Laboratories Ltd.

14 Feb 2025

112.70

4.40%

Board Meeting

CHOKSI LABORATORIES LTD. - 526546 - Board Meeting Outcome for Outcome Of Board Meeting Dated 14Th …

BSE India

1. Considered and approved Unaudited Financial Results for the Quarter and Nine Month ended 31st December, 2024 along with the Limited review report; 2. Other routine businesses with the permission of Chair

pdf

Choksi Laboratories Ltd.

05 Feb 2025

112.70

4.40%

Board Meeting

CHOKSI LABORATORIES LTD. - 526546 - Board Meeting Intimation for Meeting Of Board Of Directors To …

BSE India

CHOKSI LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider and approve 1. To consider and approve the Un-Audited Financial Results of the Company for the quarter as well as nine months ended on 31st December, 2024 along with the Limited Review Report thereon; 2. Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, which shall include at least one independent Director. If any.

pdf

Is Choksi Laboratories Ltd. worth buying?

8 Votes:

Buy 37.5%

Sell 25.0%

Hold 37.5%